The Cambridge Clostridium difficile Study
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea
This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group
The patient group given Lab4 probiotics (Group 2) experienced a lower incidence of Clostridium difficile diarrhoea compared to the placebo (Group 1).
This effect was due to a reduction in the presence of the Clostridium difficile toxin in Group 2.
Supplementation with Lab4 probiotics can reduce the incidence of C. difficile diarrhoea in hospitalised patients.